Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) shares up in the sky after this update

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) stock soared 17.36% to $1.42 in the pre-market trading session following an announcement by a biopharmaceutical corporation focusing on advancing immunology-based treatments for common inflammatory disorders that two collaboration have been reached to explore potential therapeutic applications for its immunomodulatory drug, Ampion.

The Organization has entered into a cooperative study arrangement with the oldest and one of the top children’s hospitals in the United States, whereby both sides will partner and perform exploratory research to assess whether Ampion’s anti-inflammatory and signaling mechanisms could play a role in the treatment of certain rare pediatric inflammatory diseases.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Most Popular

Related posts